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Efficacy of carboplatin (C ) and etoposide (E ) for extensive stage 
small cell lung cancer (ED-SCLC)
Yilmaz, Ufuk; Halilcolar, Huseyin; Yapicioglu, Sena;  
Yildirim, Yasemin; Unsal, Ipek; Mahlec, Ceyda 
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Izmir, Turkey
Background: Standard chemotherapy for SCLC is considered to be a 
cisplatin based combination. C has broad spectrum anti-tumor activ-
ity and is commonly used as a less toxic alternative to cisplatin. The 
purpose of this study is to investigate the activity and toxicity of C and 
E in patients (pts) with previously untreated ED- SCLC. 
Methods: Patients characteristics included pathologically diagnosed 
extensive SCLC, measurable or evaluable disease, ECOG performance 
status (PS) 0-3, and adequate organ function. Chemotherapy consisted 
of ( C ) AUC 6 IV day 1, ( E ) 100 mg/m2IV day 1-3. This schedule was 
repeated every 21 days for maximum 6 cycles. Data were collected pro-
spectively. Survival data was calculated from date of treatment to date 
of death or last known follow up. Kaplan-Meier curves and Log Rank 
test were used for studying survival rates.
Results: From 01/01 to 11/06, 56 Chemotherapy and radiotherapy 
naive pts were enrolled and 52 were evaluable. Patients characteristics 
were as follows: median age 62 years (range 39-76); 50 male and 2 
female; ECOG PS 0-1 in 43 pts, PS 2-3 in 9 pts. 14 pts had multi-organ 
metastasis. 33 patients died. Seven patients lost to follow up. A total of 
243 cycles were administered: median 4.68 (range 1-6). Dose reduc-
tions took place in 2.8% of cycles. The overall response rate was 71% 
(25% CR, 46% PR). Median overall survival was 337 days (95% [CI 
272-401]), one-year and two years survival were 44.8% and 13.3%, 
respectively. Log Rank test demonstrated that multi-organ metastasis 
lead to a trend to the poor survival (P=0.055). Grade III-IV neutrope-
nia, leukopenia, thrombocytopenia, anemia were detected in 16%, 6%, 
4.5%, 3.7% of courses, respectively. Febrile neutropenia was developed 
in 5 patients. There was no toxic death. Non-hematological toxicity was 
generally mild.
Conclusions: On the basis of these results, It seems that C+E is active 
and tolerable in ED-SCLC patients and our outcomes are in line with 
other published platinum-based studies.
SCLC: Molecular Targeted Therapy
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N-cadherin, a potential novel therapeutic target in small cell lung 
cancer
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Background: New treatment ideas are needed in small cell lung cancer 
(SCLC). N-cadherin which is associated with increased tumor invasive-
ness is a potential novel therapeutic target. It seems reasonable to test 
recently developed cyclic peptide N-cadherin antagonists in tumors 
with high N-cadherin expression, and it seemed likely that high N-cad-
herin expression would occur more frequently in aggressive tumors like 
SCLC. Our objective was to determine the frequency and biological 
signiﬁcance of N-cadherin expression in SCLC.
Methods: We retrospectively analyzed 86 patients with small cell 
lung cancer, most of whom received treatment: chemotherapy with 
or without radiation. We reviewed their clinical charts and obtained: 
date of diagnosis, age, gender, performance status, treatment dates and 
treatment response (CR/PR, stable disease, progression), and death or 
last encounter date. We also analyzed their pathology specimens for 
frequency of expression of N-cadherin and grouped them into three cat-
egories: no expression, some expression of N-cadherin >1% but <35%, 
and strong expression 36-100%. Subsequently, we determined the 
correlation between the N-cadherin frequency groups and the overall 
survival for all 86 patients. We also determined the time to progression 
in a subset of 56 patients (with available treatment response data).
Results: Out of the 86 patients, 18 (21%) did not express N-cadherin, 
10 (11.6%) patients showed >1% but <35% expression of N-cadherin, 
and 58 (67.4%) had a strong expression >36%-100%. There was no 
association found between N-cadherin expression and overall survival 
using either the Log-Rank Test or the Wilcoxon Test. In the subset of 
56 patients with available treatment response data there was no associa-
tion between N-cadherin expression and progression free survival. 
Conclusions: N-cadherin was expressed relatively frequently in this 
group of SCLC patients, and these results suggest that phase II trials of 
the novel cyclic peptide N-cadherin antagonists are warranted in SCLC. 
N-cadherin did not appear to have prognostic value in our study.
SCLC: Radiation
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Once a day (QD) thoracic 3D conformal radiotherapy (XRT) for 
patients with limited stage small-cell lung cancer (SCLC) treated 
concurrently with etoposide and cisplatin (EP): results of a single 
institution retrospective experience.
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Dominique1 Depagne, Corinne1 Nesme, Pascale1 Guerin, Jean-Claude1 
Perol, Maurice1 
1 Hospices Civils de Lyon, Lyon, France 2 Léon Bérard Regional Can-
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Background: Standard treatment of limited-stage SCLC is based on 
EP chemotherapy (CT) given concurrently with early twice a day (BID) 
thoracic XRT (45 Gy in 30 fractions) and prophylactic cranial irradia-
tion (PCI) in case of complete response (CR). BID thoracic XRT is dif-
ﬁcult in common practice and often causes severe esophagitis. Option 
of a more convenient QD schedule with a higher dose conformal 3D 
XRT needs to be studied. 
Patients and Methods: Patients (pts) with limited-stage SCLC re-
ceived P (100 mg/m2 d1) - E (100 mg/m2 d1-3) for 4 courses adminis-
tered every 3 weeks with a 20% dose reduction during XRT (cycle 2 
and 3). QD 3D conformal thoracic XRT began concurrently with the 
second course and delivered 60 Gy (30 fractions of 2 Gy) in 6 weeks. 
PCI (24 Gy, 12 fractions) was given for complete responders. Results 
were retrospectively analysed.
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Results: From 1996 to 2004, 38 consecutive pts (median age 61 
(42-77), PS 0-1: 92%, 2-3: 8%) were treated. 84% pts received 4 CT 
cycles and 86% pts full thoracic XRT; 26 pts underwent PCI. Objec-
tive response rate is 84% with 53% CR. With a median follow-up of 26 
months, median disease-free survival, median survival and 5-year sur-
vival rate are respectively 10,6 months [7,3-15,3], 17,6 months [11,0-
31,7] and 29%. Intrathoracic inﬁeld and brain isolated failures occurred 
in respectively in 30% and 22% pts. Main toxicities were neutropenia 
(55% grade 4 neutropenia with 4 deaths due to febrile neutropenia con-
cerning PS 2-3 and elderly pts) and esophagitis (29% grade 3+). Grade 
2+ radiation pneumonitis occurred in 5% of pts.
Conclusion: High dose QD XRT given concurrently with EP CT is 
feasible but must be restricted to good PS patients. Esophagitis remains 
a limiting toxicity. In spite of broad inclusion criteria (no limit of age, 
PS 2-3), median and 5-year survival rate are similar to those reported 
by Turrisi et al. NEJM, 340(4)265-271,1999. These results justify the 
CONVERT phase III study wich will compare QD high dose XRT (66 
Gy) to BID thoracic XRT (45 Gy) given concurrently with EP CT in 
limited-stage SCLC.
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A long-term result by hyperfractionated radiotherapy with 
concurrent chemotherapy for limited-stage small cell lung cancer 
(LD-SCLC): a retrospective analysis in a single institution
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Purpose: To determine the long-term treatment results of hyperfrac-
tionated thoracic radiotherapy with concurrent chemotherapy for clini-
cally diagnosed LD-SCLC patients.
Materials and Methods: Between 1996 and 2004, 46 patients with 
histologically conﬁrmed SCLC were diagnosed with limited-stage 
disease using physical and radiological examinations. Patient character-
istics. Gender: M/F=36/10. Median age: 64 years (21-82), Performance 
status: 0/1/2=13/30/3, T1/2/3/4=8/11/7/20, N0/1/2/3=3/5/25/13, Clini-
cal stage: 2A/2B/3A/3B=1/4/17/24. For chemotherapy, dose-intensive 
(DI) regimens such as CODE and CAV containing doxorubicin were 
preferably used as a neoadjuvant setting before 1998, and, combina-
tions of cisplatin or carboplatin with etoposide or CPT-11 (PE/CPT) 
were used after 1998. Twice-daily thoracic radiotherapy was performed 
with 6/10 MV- X rays with at least a 6-hour interval and total dose was 
45 Gy/1.5 Gy bid in 3 weeks. Radiotherapy was started on day 1 im-
mediately after the 1st/2nd/3rd/4th cycle of chemotherapy (cisplatin: 80 
mg/m2 i.v. on day 0 and etoposide: 100 mg/m2 p.o.) in 18/13/3/12 pts, 
respectively. Primary lesions and enlarged lymph nodes with ipsilateral 
hilum and mediastimum (also with supraclavicular region, when neces-
sary) were covered with AP portals of 30 Gy, then gross tumor volumes 
were irradiated with oblique portals of 15 Gy. A prophylactic cranial 
irradiation (PCI) of 24-30 Gy/2.0-2.5 Gy was used in selected cases. 
Local tumor responses were assessed by RECIST. Survical results were 
analysed by the Kaplan-Meier method. Treatment-related toxicities 
were evaluated according to the CTCAE v3.0.
Results: All of the patients could successfully receive 45 Gy of ir-
radiation. Four cycles of scheduled chemotherapy mostly at a 3-week 
interval were completed in 41 out of 46 patients (89%). This combined 
treatment resulted in an overall response rate of 98%, including 59% 
(27/46) complete responses. Loco-regional recurrences were detected 
on follow-up CT scans in 27% (12/46) of cases, all of which were 
detected within gross tumor volumes at the time of treatment plan-
ning. No clinical/treatment factors were signiﬁcantly correlated to 
local recurrence. Distant metastasis were found in 67% (30/46), and 
the most frequent site of ﬁrst metastasis was brain (39%), while PCI 
were done in 33% (15/46). Overall 46% of the patients were diagnosed 
with brain metastases at some time and subsequently treated by a pal-
liative radiotherapy. For all patients, the median survival time (MST) 
was 22.7 months and the 2/3/5 year survival rates were 44/32/22%. 
The group of the patients treated with standard PE/CPT showed better 
survival than that with DI regimens. (p<0.05; Wilcoxon). With standard 
PE/CPT, MST was 28.6 months and the 2/3/5/ year survival rates were 
51/32/24%. Timing of radiation and chemotherapy, use of PCI did not 
signiﬁcantly impact on survivals in this study. The major toxicities 
included grade 3 and 4 acute neutropenia (15% and 64%, respectively), 
grade 2 and 3 radiation esophagitis (24% and 4%). Radiation pneu-
monitis were observed as grade 2 and 3 in 7% and 13%, respectively, 
and one patient died from severe radiation pneumonia and subsequent 
infectious events. 
Conclusions: Hyperfractionated radiation with concurrent chemothera-
py was well tolerated and showed favorable responses and survivals in 
patients with LD-SCLC. Standard PE/CPT showed a superior survival 
rate to DI regimens. For further improvement of clinical results for 
LD-SCLC, more effective means of prophylaxis/treatment against brain 
metastasis should be established.
